News & Updates

Show Multimedia Only

Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?

23 Oct 2022 by

A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.

23 Oct 2022

Mitokine levels predict COPD outcomes

19 Oct 2022

In patients with chronic obstructive pulmonary disease (COPD), mitokine levels are elevated and are associated with important clinical outcomes such as disease exacerbation and exercise capacity, a recent study has found.

19 Oct 2022

Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?

16 Oct 2022 by

The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.

16 Oct 2022

Pemetrexed-based chemo boosts survival in NSCLC

15 Oct 2022

As an add-on to gefitinib monotherapy, pemetrexed-based chemotherapy improves survival outcomes in nonsmall cell lung cancer (NSCLC) patients harbouring EGFR mutations, a recent study has found.

15 Oct 2022

Lipid profile tied to outcomes in lung squamous cell carcinoma

15 Oct 2022

Among patients with lung squamous cell carcinoma (LUSC), lower levels of high-density lipoprotein cholesterol (HDL-C) appear to aggravate the risk of worse outcomes, a recent study has found.

15 Oct 2022

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

15 Oct 2022

New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

15 Oct 2022

Glaucoma more prevalent in women with COPD

14 Oct 2022

The risk of open-angle glaucoma (OAG) appears to be aggravated among women with chronic obstructive pulmonary disease (COPD), reports a recent study.

14 Oct 2022

Antidepressant med may double as sleep apnoea treatment

13 Oct 2022 by

The antidepressant reboxetine demonstrates therapeutic potential in patients with obstructive sleep apnoea (OSA), with a recent study showing that the drug helps lower disease severity.

13 Oct 2022

Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?

11 Oct 2022 by

The use of metformin, fluvoxamine, or ivermectin in an outpatient setting did not appear to prevent progression to severe COVID-19, according to results of the phase III COVID-OUT trial.

11 Oct 2022

Unilateral pleural effusion mars diaphragmatic function, causes hyperactivity

10 Oct 2022

Unilateral pleural effusion impairs the ipsilateral hemidiaphragm function and sets off compensatory hyperactivity of the contralateral hemidiaphragm, which resolves postdrainage, suggest the results of the second PLeural Effusion And Symptom Evaluation (PLEASE-2) study.

10 Oct 2022

News & Updates

Showing Respirology articles

Showing

Specialty:

Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?

Mitokine levels predict COPD outcomes

Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?

Pemetrexed-based chemo boosts survival in NSCLC

Lipid profile tied to outcomes in lung squamous cell carcinoma

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

Glaucoma more prevalent in women with COPD

Antidepressant med may double as sleep apnoea treatment

Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?

Unilateral pleural effusion mars diaphragmatic function, causes hyperactivity